Arbutus Biopharma Corporation ABUS Liability related to sale of future royalties
Liability related to sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's liability related to sale of future royalties?
- Arbutus Biopharma Corporation (ABUS) reported liability related to sale of future royalties of $3.28M in Q1 2026.
- How has Arbutus Biopharma Corporation's liability related to sale of future royalties changed year-over-year?
- Arbutus Biopharma Corporation's liability related to sale of future royalties decreased by 25.7% year-over-year, from $4.41M to $3.28M.
- What is the long-term trend for Arbutus Biopharma Corporation's liability related to sale of future royalties?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's liability related to sale of future royalties has grown at a -29.3% compound annual growth rate (CAGR), from $19.55M to $3.44M.
- What does liability related to sale of future royalties mean?
- This represents the non-current portion of financial obligations arising from the monetization of future royalty streams. It reflects capital raised by selling the rights to future revenue generated from licensed intellectual property or drug candidates. This liability is settled over time as the underlying royalties are earned and paid to the counterparty.